{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:12:38Z","timestamp":1793502758572,"version":"4.5.0"},"reference-count":56,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2023,3,4]],"date-time":"2023-03-04T00:00:00Z","timestamp":1677888000000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To assess the relationship between renal function and efficacy\/safety of imipenem\/cilastatin\/relebactam for the treatment of hospital-acquired\/ventilator-associated pneumonia (HABP\/VABP) from RESTORE-IMI 2 and determine the PTA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Adults with HABP\/VABP were randomized 1:1 to IV imipenem\/cilastatin\/relebactam 1.25\u2005g or piperacillin\/tazobactam 4.5\u2005g every 6\u2005h for 7\u201314\u2005days. Initial doses were selected by CLCR and adjusted thereafter, as appropriate. Outcomes included Day 28 all-cause mortality (ACM), clinical response, microbiological response and adverse events. Population pharmacokinetic modelling and Monte Carlo simulations assessed PTA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The modified ITT population comprised those with normal renal function (n\u200a=\u200a188), augmented renal clearance (ARC; n\u200a=\u200a88), mild renal impairment (RI; n\u200a=\u200a124), moderate RI (n\u200a=\u200a109) and severe RI (n\u200a=\u200a22). ACM rates were comparable between treatment arms among all baseline renal function categories. Clinical response rates were comparable between treatment arms for participants with RI and normal renal function but were higher (91.7% versus 44.4%) for imipenem\/cilastatin\/relebactam-treated versus piperacillin\/tazobactam-treated participants with CLCR \u2265250\u2005mL\/min (n\u200a=\u200a21). Microbiologic response rates were comparable between treatment arms for participants with RI but higher among those treated with imipenem\/cilastatin\/relebactam in participants with CLCR \u226590\u2005mL\/min (86.6% versus 67.2%). Adverse events were comparable between treatment arms across renal function categories. Joint PTA was &amp;gt;98% for key pathogen MICs for susceptible pathogens (MIC \u22642\u2005mg\/L).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Prescribing information\u2013defined dose adjustments in participants with baseline RI and full dosing of imipenem\/cilastatin\/relebactam 1.25\u2005g every 6\u2005h for participants with normal renal function or augmented renal clearance achieved sufficiently high drug exposures and favourable safety and efficacy profiles.<\/jats:p><\/jats:sec>","DOI":"10.1093\/jacamr\/dlad011","type":"journal-article","created":{"date-parts":[[2023,3,4]],"date-time":"2023-03-04T12:43:27Z","timestamp":1677933807000},"source":"Crossref","is-referenced-by-count":19,"title":["Imipenem\/cilastatin\/relebactam efficacy, safety and probability of target attainment in adults with hospital-acquired or ventilator-associated bacterial pneumonia among patients with baseline renal impairment, normal renal function, and augmented renal clearance"],"prefix":"10.1093","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6218-435X","authenticated-orcid":false,"given":"Jason A","family":"Roberts","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Centre for Clinical Research, The University of Queensland , Brisbane , Australia"},{"name":"Herston Infectious Diseases Institute (HeIDI), Metro North Health , Brisbane , Australia"},{"name":"Departments of Pharmacy and Intensive Care Medicine, Royal Brisbane and Women\u2019s Hospital , Brisbane , Australia"},{"name":"Division of Anesthesiology Critical Care Emergency and Pain Medicine, N\u00eemes University Hospital, University of Montpellier , N\u00eemes , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4148-0165","authenticated-orcid":false,"given":"David P","family":"Nicolau","sequence":"additional","affiliation":[{"name":"Center for Anti-Infective Research & Development, Hartford Hospital , Hartford, CT , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Martin-Loeches","sequence":"additional","affiliation":[{"name":"Department of Intensive Care Medicine, St James\u2019s Hospital , Dublin , Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C Andrew","family":"Deryke","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. , Rahway, NJ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria C","family":"Losada","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. , Rahway, NJ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiejun","family":"Du","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. , Rahway, NJ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munjal","family":"Patel","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. , Rahway, NJ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew L","family":"Rizk","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. , Rahway, NJ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Paschke","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. , Rahway, NJ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke F","family":"Chen","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. , Rahway, NJ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,3,4]]},"reference":[{"key":"2023030412431015100_","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2023030412431015100_","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1306801","article-title":"Multistate point-prevalence survey of health care-associated infections","volume":"370","author":"Magill","year":"2014","journal-title":"N Engl J Med"},{"key":"2023030412431015100_","doi-asserted-by":"crossref","first-page":"e602","DOI":"10.1093\/cid\/ciaa1712","article-title":"Trends in hospital-acquired and ventilator-associated bacterial pneumonia trials","volume":"73","author":"Bart","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023030412431015100_","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/CCM.0000000000005298","article-title":"Descriptive epidemiology and outcomes of nonventilated hospital-acquired, ventilated hospital-acquired, and ventilator-associated bacterial pneumonia in the United States, 2012\u20132019","volume":"50","author":"Zilberberg","year":"2021","journal-title":"Crit Care Med"},{"key":"2023030412431015100_","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Antimicrobial Resistance Collaborators","year":"2022","journal-title":"Lancet"},{"key":"2023030412431015100_","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jinf.2014.10.004","article-title":"Resistance patterns and outcomes in intensive care unit (ICU)-acquired pneumonia. Validation of European Centre for Disease Prevention and Control (ECDC) and the Centers for Disease Control and Prevention (CDC) classification of multidrug resistant organisms","volume":"70","author":"Martin-Loeches","year":"2015","journal-title":"J Infect"},{"key":"2023030412431015100_","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3390\/antibiotics9070393","article-title":"Augmented renal clearance and how to augment antibiotic dosing","volume":"9","author":"Chen","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"2023030412431015100_","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coph.2015.06.002","article-title":"Augmented renal clearance in critically ill patients: etiology, definition and implications for beta-lactam dose optimization","volume":"24","author":"Sime","year":"2015","journal-title":"Curr Opin Pharmacol"},{"key":"2023030412431015100_","first-page":"1079","article-title":"Epidemiology of augmented renal clearance in mixed ICU patients","volume":"81","author":"De Waele","year":"2015","journal-title":"Minerva Anestesiol"},{"key":"2023030412431015100_","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1097\/CCM.0000000000000029","article-title":"Augmented renal clearance in the ICU: results of a multicenter observational study of renal function in critically ill patients with normal plasma creatinine concentrations","volume":"42","author":"Udy","year":"2014","journal-title":"Crit Care Med"},{"key":"2023030412431015100_","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3390\/pharmaceutics9030036","article-title":"Augmented renal clearance in critical illness: an important consideration in drug dosing","volume":"9","author":"Mahmoud","year":"2017","journal-title":"Pharmaceutics"},{"key":"2023030412431015100_","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1378\/chest.11-1671","article-title":"Subtherapeutic initial \u03b2-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations","volume":"142","author":"Udy","year":"2012","journal-title":"Chest"},{"key":"2023030412431015100_","doi-asserted-by":"crossref","first-page":"R84","DOI":"10.1186\/cc12705","article-title":"Meropenem and piperacillin\/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic\/pharmacodynamic target attainment when extended infusions are used?","volume":"17","author":"Carlier","year":"2013","journal-title":"Crit Care"},{"key":"2023030412431015100_","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1097\/CCM.0b013e318168fbe0","article-title":"Acute kidney injury criteria predict outcomes of critically ill patients","volume":"36","author":"Barrantes","year":"2008","journal-title":"Crit Care Med"},{"key":"2023030412431015100_","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/jama.294.7.813","article-title":"Acute renal failure in critically ill patients: a multinational, multicenter study","volume":"294","author":"Uchino","year":"2005","journal-title":"JAMA"},{"key":"2023030412431015100_","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s00134-015-3934-7","article-title":"Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study","volume":"41","author":"Hoste","year":"2015","journal-title":"Intensive Care Med"},{"key":"2023030412431015100_","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s13054-015-0920-y","article-title":"Evolution of chronic renal impairment and long-term mortality after de novo acute kidney injury in the critically ill; a Swedish multi-centre cohort study","volume":"19","author":"Rimes-Stigare","year":"2015","journal-title":"Crit Care"},{"key":"2023030412431015100_","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1093\/cid\/ciy790","article-title":"Renal dosing of antibiotics: are we jumping the gun?","volume":"68","author":"Crass","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2023030412431015100_","first-page":"2286","article-title":"Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa","volume":"68","author":"Livermore","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2023030412431015100_","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1093\/jac\/dky107","article-title":"In vitro activity of imipenem\/relebactam against Gram-negative ESKAPE pathogens isolated in 17 European countries: 2015 SMART surveillance programme","volume":"73","author":"Karlowsky","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2023030412431015100_","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.diagmicrobio.2017.02.018","article-title":"In vitro activity of imipenem-relebactam against gram-negative bacilli isolated from patients with lower respiratory tract infections in the United States in 2015\u2014results from the SMART global surveillance program","volume":"88","author":"Lob","year":"2017","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2023030412431015100_","doi-asserted-by":"crossref","first-page":"105841","DOI":"10.1016\/j.ijantimicag.2019.10.022","article-title":"In-vitro activity of imipenem\/relebactam and key \u03b2-lactam agents against Gram-negative bacilli isolated from lower respiratory tract infection samples of intensive care unit patients\u2014SMART Surveillance United States 2015\u20132017","volume":"55","author":"Karlowsky","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"2023030412431015100_","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1093\/jpids\/piaa056","article-title":"In vitro activity of imipenem\/relebactam against gram-negative bacilli from pediatric patients\u2014study for monitoring antimicrobial resistance trends (SMART) global surveillance program 2015\u20132017","volume":"10","author":"Karlowsky","year":"2021","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2023030412431015100_","doi-asserted-by":"crossref","first-page":"e4539","DOI":"10.1093\/cid\/ciaa803","article-title":"A randomized, double-blind, multicenter trial comparing efficacy and safety of imipenem\/cilastatin\/relebactam versus piperacillin\/tazobactam in adults with hospital-acquired or ventilator-associated bacterial pneumonia (RESTORE-IMI 2 study)","volume":"73","author":"Titov","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023030412431015100_","article-title":"RECARBRIO\u2122 (imipenem\/cilastatin and relebactam) for injection, for intravenous use. Prescribing information","author":"Merck Sharp & Dohme Corp","year":"2020"},{"key":"2023030412431015100_","doi-asserted-by":"crossref","first-page":"e00280-18","DOI":"10.1128\/AAC.00280-18","article-title":"Pharmacokinetics, safety, and tolerability of single and multiple doses of relebactam, a \u03b2-lactamase inhibitor, in combination with imipenem and cilastatin in healthy participants","volume":"62","author":"Rhee","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2023030412431015100_","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"2023030412431015100_","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/cts.13158","article-title":"Population pharmacokinetic\/pharmacodynamic assessment of imipenem\/cilastatin\/relebactam in patients with hospital-acquired\/ventilator-associated bacterial pneumonia","volume":"15","author":"Patel","year":"2022","journal-title":"Clin Transl Sci"},{"key":"2023030412431015100_","article-title":"Imipenem\/relebactam pharmacokinetic\/pharmacodynamic analyses from an in vivo neutropenic mouse delayed lung infection model","author":"Daryani","year":"2020"},{"key":"2023030412431015100_","article-title":"Imipenem\/relebactam pharmacokinetic\/pharmacodynamic analyses from an in vivo neutropenic murine thigh infection model","author":"Patel","year":"2020"},{"key":"2023030412431015100_","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/sim.4780040211","article-title":"Comparative analysis of two rates","volume":"4","author":"Miettinen","year":"1985","journal-title":"Stat Med"},{"key":"2023030412431015100_","article-title":"Breakpoint tables for interpretation of MICs and zone diameters, version 11.0","author":"EUCAST"},{"key":"2023030412431015100_","doi-asserted-by":"crossref","first-page":"e00731-20","DOI":"10.1128\/AAC.00731-20","article-title":"Outcomes in participants with renal impairment from a phase 3 clinical trial for ceftolozane\/tazobactam treatment of nosocomial pneumonia (ASPECT-NP)","volume":"64","author":"Huntington","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2023030412431015100_","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/cid\/ciw133","article-title":"Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program","volume":"62","author":"Mazuski","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2023030412431015100_","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1046\/j.1523-1755.2002.00509.x","article-title":"Renal failure in the ICU: comparison of the impact of acute renal failure and end-stage renal disease on ICU outcomes","volume":"62","author":"Clermont","year":"2002","journal-title":"Kidney Int"},{"key":"2023030412431015100_","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S1473-3099(14)70036-2","article-title":"Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions","volume":"14","author":"Roberts","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"2023030412431015100_","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper","volume":"46","author":"Abdul-Aziz","year":"2020","journal-title":"Intensive Care Med"},{"key":"2023030412431015100_","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2023030412431015100_","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s00134-015-4188-0","article-title":"Beta-lactam infusion in severe sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis","volume":"42","author":"Abdul-Aziz","year":"2016","journal-title":"Intensive Care Med"},{"key":"2023030412431015100_","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/cid\/ciy258","article-title":"Extended vs bolus infusion of broad-spectrum \u03b2-lactams for febrile neutropenia: an unblinded, randomized trial","volume":"67","author":"Ram","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2023030412431015100_","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S1473-3099(17)30615-1","article-title":"Prolonged versus short-term intravenous infusion of antipseudomonal \u03b2-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials","volume":"18","author":"Vardakas","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2023030412431015100_","article-title":"Zosyn\u00ae (piperacillin and tazobactam). Prescribing Information","author":"Wyeth Pharmaceuticals Inc","year":"2017"},{"key":"2023030412431015100_","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13054-019-2308-x","article-title":"Increased dosing regimens of piperacillin-tazobactam are needed to avoid subtherapeutic exposure in critically ill patients with augmented renal clearance","volume":"23","author":"Besnard","year":"2019","journal-title":"Crit Care"},{"key":"2023030412431015100_","doi-asserted-by":"crossref","first-page":"e02306-17","DOI":"10.1128\/AAC.02306-17","article-title":"Population pharmacokinetics of piperacillin in sepsis patients: should alternative dosing strategies be considered?","volume":"62","author":"Andersen","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2023030412431015100_","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13054-015-0750-y","article-title":"Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance?","volume":"19","author":"Udy","year":"2015","journal-title":"Crit Care"},{"key":"2023030412431015100_","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jcrc.2018.08.026","article-title":"Higher than standard dosing regimen are needed to achieve optimal antibiotic exposure in critically ill patients with augmented renal clearance receiving piperacillin-tazobactam administered by continuous infusion","volume":"48","author":"Carri\u00e9","year":"2018","journal-title":"J Crit Care"},{"key":"2023030412431015100_","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.ijantimicag.2017.12.015","article-title":"Population pharmacokinetics of continuous infusion of piperacillin in critically ill patients","volume":"51","author":"Dhaese","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"2023030412431015100_","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing-Thirty Second Edition: M100","author":"CLSI","year":"2022"},{"key":"2023030412431015100_","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1093\/jac\/dkac261","article-title":"Imipenem\/cilastatin\/relebactam pharmacokinetics in critically ill patients with augmented renal clearance","volume":"77","author":"Fratoni","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2023030412431015100_","article-title":"Relebactam","author":"Hilbert","year":"2021"},{"key":"2023030412431015100_","article-title":"Relebactam increases susceptibility of Enterobacterales and Pseudomonas aeruginosa to imipenem in both imipenem-susceptible and imipenem-nonsusceptible gram-negative bacteria- global SMART 2017\u20132019","author":"Hilbert","year":"2021"},{"key":"2023030412431015100_","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.jcrc.2013.03.003","article-title":"Augmented renal clearance is a common finding with worse clinical outcome in critically ill patients receiving antimicrobial therapy","volume":"28","author":"Claus","year":"2013","journal-title":"J Crit Care"},{"key":"2023030412431015100_","doi-asserted-by":"crossref","first-page":"R218","DOI":"10.1186\/cc11862","article-title":"A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia","volume":"16","author":"Kollef","year":"2012","journal-title":"Crit Care"},{"key":"2023030412431015100_","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/cid\/ciu219","article-title":"A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia","volume":"59","author":"Awad","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2023030412431015100_","doi-asserted-by":"crossref","first-page":"642","DOI":"10.2146\/ajhp080200","article-title":"Estimation of creatinine clearance in morbidly obese patients","volume":"66","author":"Demirovic","year":"2009","journal-title":"Am J Health Syst Pharm"},{"key":"2023030412431015100_","doi-asserted-by":"crossref","first-page":"111","DOI":"10.12793\/tcp.2018.26.3.111","article-title":"Augmented renal clearance","volume":"26","author":"Atkinson","year":"2018","journal-title":"Transl Clin Pharmacol"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/5\/2\/dlad011\/49422577\/dlad011.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/5\/2\/dlad011\/49422577\/dlad011.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T01:28:27Z","timestamp":1701826107000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/doi\/10.1093\/jacamr\/dlad011\/7069577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,2]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlad011","relation":{},"ISSN":["2632-1823"],"issn-type":[{"value":"2632-1823","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,4,1]]},"published":{"date-parts":[[2023,3,2]]},"article-number":"dlad011"}}